What's in Zydus Lifesciences Limited's pipeline?

Zydus Lifesciences Limited has 8 drugs in our index: 0 marketed, 0 filed, 3 in Phase 3, 2 in Phase 2, 3 in Phase 1.

Which companies overlap with Zydus Lifesciences Limited's portfolio?

Top competitors by shared drug class: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Hoffmann-La Roche, RemeGen Co., Ltd., Samsung Bioepis Co., Ltd., Shanghai Henlius Biotech.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/zydus-lifesciences-limited.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Zydus Lifesciences Limited — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Zydus Lifesciences Limited pipeline: 0 marketed, 0 filed, 3 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 2 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Desidustat Oral Tablet	Desidustat Oral Tablet	phase 3	PHD inhibitor	Prolyl hydroxylase domain-containing proteins (PHD)	Hematology
Pertuzumab (Perjeta®)	Pertuzumab (Perjeta®)	phase 3	HER2 inhibitor monoclonal antibody	HER2 (Human Epidermal Growth Factor Receptor 2)	Oncology
Pertuzumab (ZRC-3277)	Pertuzumab (ZRC-3277)	phase 3	HER2-targeted monoclonal antibody	HER2 (Human Epidermal Growth Factor Receptor 2)	Oncology

Therapeutic area mix

Oncology · 2
Hematology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · 2 shared drug classes
Hoffmann-La Roche · 2 shared drug classes
RemeGen Co., Ltd. · 1 shared drug class
Samsung Bioepis Co., Ltd. · 1 shared drug class
Shanghai Henlius Biotech · 1 shared drug class
Spanish Breast Cancer Research Group · 1 shared drug class
Biocon Biologics UK PLC · 1 shared drug class
Tanvex BioPharma USA, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Zydus Lifesciences Limited:

Cite this brief

Drug Landscape (2026). Zydus Lifesciences Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/zydus-lifesciences-limited. Accessed 2026-05-17.